Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Oncopeptides Innovation AB currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that each active case is being handled by a different examiner in a separate technical department.
NOTTINGHAM, KYLE GREGORY is the busiest examiner for the portfolio, with 1 pending office action. Given the total volume of active matters, the workload is split between the two distinct examiners. This lack of overlap means that no single examiner has a dominant influence over the company's current prosecution efforts.
The presence of 2 distinct art units suggests a variety of technical focuses within the company's biotechnology filings. Practitioners should be prepared to navigate the specific procedural nuances of the different art units. Consistency in prosecution will depend on monitoring the progress of these separate tracks, as there is no overlap in the personnel reviewing the applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576878 | MELFLUFEN FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | JAUHARI, SACHI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18917773 | COMPOUNDS CONTAINING DEUTERIUM | NOTTINGHAM, KYLE GREGORY | — |
| 18576878 | MELFLUFEN FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | JAUHARI, SACHI | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18917773 | COMPOUNDS CONTAINING DEUTERIUM | NOTTINGHAM, KYLE GREGORY | 1621 | §112DP | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18576878 | MELFLUFEN FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | JAUHARI, SACHI | 1654 | §102§103§112Other | Non-Final OA | — | Pending | Jan 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOncopeptides Innovation AB has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kyle Gregory Nottingham has the most, with 1 of Oncopeptides Innovation AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
